Baidu
map

J Microbiol Immunol Infect:早发性湿疹与牛奶过敏、鼻炎和哮喘风险的增加相关

2019-06-11 AlexYang MedSci原创

过敏性湿疹和食物过敏经常在儿童早期发生。然而,湿疹起始与过敏原敏感有关的特应性疾病的发生的相关性的关系仍旧不清楚。最近,有研究人员跟踪调查了186名儿童,跟踪调查为期4年。研究人员将儿童分成3个小组:早发性湿疹组(小于2岁,n=55),晚发性湿疹组(不小于2岁,n=40)和不具有湿疹组(n=91)。研究发现,在具有早发性湿疹组中,食物过敏,尤其是牛奶过敏患病率与1、1.5、2、3和4岁的没有湿疹的

过敏性湿疹和食物过敏经常在儿童早期发生。然而,湿疹起始与过敏原敏感有关的特应性疾病的发生的相关性的关系仍旧不清楚。

最近,有研究人员跟踪调查了186名儿童,跟踪调查为期4年。研究人员将儿童分成3个小组:早发性湿疹组(小于2岁,n=55),晚发性湿疹组(不小于2岁,n=40)和不具有湿疹组(n=91)。研究发现,在具有早发性湿疹组中,食物过敏,尤其是牛奶过敏患病率与1、1.5、2、3和4岁的没有湿疹的参与者相比显著更高。更多的是,早发性湿疹或者晚发性湿疹组中1.5岁的患者的嗜酸性粒细胞数目显著更多。另外,早发性和晚发性湿疹与过敏性鼻炎更高的患病率在2、3和4岁时显著相关,在哮喘患者中为2岁。更多的是,早发性湿疹组的过敏性鼻炎(p=0.010)和哮喘(p=0.032)在4岁时风险显著增加。

最后,研究人员指出,早发性湿疹(小于2岁)儿童应该与儿童早期牛奶过敏患病率的增加和鼻炎哮喘风险的增加相关。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2023085, encodeId=443c20230858e, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Mar 05 08:53:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664073, encodeId=c98d16640e359, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Mon May 04 14:53:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767662, encodeId=21611e676626a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Aug 01 07:53:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857804, encodeId=8713185e80469, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Mar 02 02:53:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084528, encodeId=96bb2084528ff, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Aug 16 03:53:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918730, encodeId=d5911918e30b3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Oct 19 01:53:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984105, encodeId=b0f5198410597, content=<a href='/topic/show?id=3c806e7596e' target=_blank style='color:#2F92EE;'>#牛奶过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67759, encryptionId=3c806e7596e, topicName=牛奶过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jul 29 20:53:00 CST 2019, time=2019-07-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2023085, encodeId=443c20230858e, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Mar 05 08:53:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664073, encodeId=c98d16640e359, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Mon May 04 14:53:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767662, encodeId=21611e676626a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Aug 01 07:53:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857804, encodeId=8713185e80469, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Mar 02 02:53:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084528, encodeId=96bb2084528ff, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Aug 16 03:53:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918730, encodeId=d5911918e30b3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Oct 19 01:53:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984105, encodeId=b0f5198410597, content=<a href='/topic/show?id=3c806e7596e' target=_blank style='color:#2F92EE;'>#牛奶过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67759, encryptionId=3c806e7596e, topicName=牛奶过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jul 29 20:53:00 CST 2019, time=2019-07-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2023085, encodeId=443c20230858e, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Mar 05 08:53:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664073, encodeId=c98d16640e359, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Mon May 04 14:53:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767662, encodeId=21611e676626a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Aug 01 07:53:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857804, encodeId=8713185e80469, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Mar 02 02:53:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084528, encodeId=96bb2084528ff, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Aug 16 03:53:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918730, encodeId=d5911918e30b3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Oct 19 01:53:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984105, encodeId=b0f5198410597, content=<a href='/topic/show?id=3c806e7596e' target=_blank style='color:#2F92EE;'>#牛奶过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67759, encryptionId=3c806e7596e, topicName=牛奶过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jul 29 20:53:00 CST 2019, time=2019-07-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2023085, encodeId=443c20230858e, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Mar 05 08:53:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664073, encodeId=c98d16640e359, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Mon May 04 14:53:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767662, encodeId=21611e676626a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Aug 01 07:53:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857804, encodeId=8713185e80469, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Mar 02 02:53:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084528, encodeId=96bb2084528ff, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Aug 16 03:53:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918730, encodeId=d5911918e30b3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Oct 19 01:53:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984105, encodeId=b0f5198410597, content=<a href='/topic/show?id=3c806e7596e' target=_blank style='color:#2F92EE;'>#牛奶过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67759, encryptionId=3c806e7596e, topicName=牛奶过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jul 29 20:53:00 CST 2019, time=2019-07-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2023085, encodeId=443c20230858e, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Mar 05 08:53:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664073, encodeId=c98d16640e359, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Mon May 04 14:53:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767662, encodeId=21611e676626a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Aug 01 07:53:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857804, encodeId=8713185e80469, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Mar 02 02:53:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084528, encodeId=96bb2084528ff, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Aug 16 03:53:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918730, encodeId=d5911918e30b3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Oct 19 01:53:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984105, encodeId=b0f5198410597, content=<a href='/topic/show?id=3c806e7596e' target=_blank style='color:#2F92EE;'>#牛奶过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67759, encryptionId=3c806e7596e, topicName=牛奶过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jul 29 20:53:00 CST 2019, time=2019-07-29, status=1, ipAttribution=)]
    2019-08-16 xjy02
  6. [GetPortalCommentsPageByObjectIdResponse(id=2023085, encodeId=443c20230858e, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Mar 05 08:53:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664073, encodeId=c98d16640e359, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Mon May 04 14:53:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767662, encodeId=21611e676626a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Aug 01 07:53:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857804, encodeId=8713185e80469, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Mar 02 02:53:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084528, encodeId=96bb2084528ff, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Aug 16 03:53:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918730, encodeId=d5911918e30b3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Oct 19 01:53:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984105, encodeId=b0f5198410597, content=<a href='/topic/show?id=3c806e7596e' target=_blank style='color:#2F92EE;'>#牛奶过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67759, encryptionId=3c806e7596e, topicName=牛奶过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jul 29 20:53:00 CST 2019, time=2019-07-29, status=1, ipAttribution=)]
    2019-10-19 sunylz
  7. [GetPortalCommentsPageByObjectIdResponse(id=2023085, encodeId=443c20230858e, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Mar 05 08:53:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664073, encodeId=c98d16640e359, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Mon May 04 14:53:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767662, encodeId=21611e676626a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Aug 01 07:53:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857804, encodeId=8713185e80469, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Mar 02 02:53:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084528, encodeId=96bb2084528ff, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Aug 16 03:53:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918730, encodeId=d5911918e30b3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Oct 19 01:53:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984105, encodeId=b0f5198410597, content=<a href='/topic/show?id=3c806e7596e' target=_blank style='color:#2F92EE;'>#牛奶过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67759, encryptionId=3c806e7596e, topicName=牛奶过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jul 29 20:53:00 CST 2019, time=2019-07-29, status=1, ipAttribution=)]

相关资讯

2018 EDF指南:特应性湿疹(特应性皮炎)的治疗

2018年3月,欧洲皮肤病学论坛(EDF)更新发布了特应性湿疹(特应性皮炎)的治疗指南,指南第1部分内容主要涵盖了相关研究方法,患者视角,一般治疗措施,基本治疗,饮食管理,局部抗炎治疗,光照疗法以及止痒治疗,第2部分内容涉及抗菌疗法,系统治疗以及变应原特异性免疫治疗,补充治疗心理咨询和教育等。

BMJ:常见沐浴露对儿童湿疹无显著治疗作用

研究人员认为在儿童湿疹标准治疗方案基础上添加润肤浴添加剂不会改善湿疹的控制效果

BMJ:治疗儿童湿疹 沐浴液添加剂成“鸡肋”?

作为一种常见疾病,儿童湿疹可能会给患儿及其家庭带来重大影响。指南建议,完整的润肤疗法是治疗湿疹的主要手段,应定期局部使用糖皮质激素或钙调神经磷酸酶抑制剂。然而,相比于更便宜的肥皂,润肤添加剂真的能获得更好的疗效吗?2018年5月,发表在《BMJ》的一项由英国科学家进行的随机对照试验,考察了润肤浴添加剂治疗儿童湿疹的疗效。

6岁患儿湿疹、反复腹泻并便血 发生了什么?

湿疹、血小板减少伴免疫缺陷,又称Wiskott‐Aldrich syndrome(WAS),是一种原发性联合免疫缺陷病。为X连锁隐性方式遗传,缺陷基因位于短臂11带上。本病发病机理还不清楚,血小板和血细胞表面糖蛋白(CD43)不稳定可能与免疫功能异常有关。

细菌疗法显示对湿疹的治疗益处

近日,根据正在进行的一项早期临床试验的初步结果显示,使用活的玫瑰单胞菌(一种天然存在于皮肤上的细菌)进行局部治疗对成人和特应性皮炎(湿疹)患儿具有有效性和安全性。在特应性皮炎的小鼠模型中进行的临床前研究表明,从健康皮肤采集的玫瑰单胞菌菌株可以缓解疾病症状。

Incyte宣布开展Ruxolitinib的III期临床试验

Incyte制药公司近日宣布,III期TRuE-AD临床试验已经招募了第1名患者,以评估ruxolitinib作为青少年和成人患者(年龄≥12岁)单药治疗特应性皮炎(AD)的长期安全性和有效性。

Baidu
map
Baidu
map
Baidu
map